r Compass Pathways, the British psychedelic technology innovation company, announced this past February 17, 2026, the new results from its second Phase 3 research trial. The study evaluated the use of COMP360 (the company’s patented synthetic version of psilocybin) for the treatment of resistant depression. The two Phase 3 trials (COMP005 and COMP006) utilised COMP360 in a total of over 800 patients. The company claims it is ready to commercialize the substance by the end of